Simris Alg AB (publ) (the “Company”) held an extraordinary general meeting on 6 March 2023. At the general meeting, the following resolutions were made.

Resolution to approve of increase in funding facility
The general meeting resolved to approve entering into a bridge loan agreement with The Brand Laboratories FZ in accordance with the board’s proposal.
The bridge loan agreement was subject to approval from the general meeting as the agreement is considered to constitute a material transaction with related parties in accordance with Chapter 16 a, of the Swedish companies act, due to the Company’s chairman of the board, Steven Schapera being associated with the Brand Laboratories.
The agreement entails an increase in the flexible financing facility by EUR 500,000 from EUR 1,000,000 to EUR 1,500,000. The entire loan must be repaid no later than August 25, 2023. Interest is charged at 1 percent per month and the Company must pay an establishment fee of 2.5 percent. As a condition of the facility increase, the withdrawn amount of up to EUR 1,500,000 will be secured through a corporate mortgage.

Resolution to amend the articles of association
The general meeting resolved to amend the articles of association in accordance with the boards’ proposal. The amendment of the articles of associations entails (i) a change of the company name to Simris Group AB, and (ii) that general meetings of the Company may be held in Simrishamn, Malmö or Stockholm.

***

For more detailed information regarding the content of the resolutions, please refer to the notice of the extraordinary general meeting published on 1 February 2023. The notice of the extraordinary general meeting and complete proposals regarding the resolutions of the general meeting are also available on the Company’s website www.simrisalg.se

Simris Alg AB Contact Details:
Julian Read
CEO Simris Alg AB
Email: ir@simris.com
Mobile: +46767888212
www.simrisalg.se

About Simris Alg AB (PUBL):
Simris Alg is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds. 
Simris Alg's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING OF SIMRIS ALG AB (PUBL)

© Modular Finance, source Nordic Press Releases